• About Us
  • Gene Therapy
    • Overview
    • Pipeline
  • News and Media
  • Careers
  • Contact Us

Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership

26 Jan , 2021 Press Releases

Spirovant leases its new, expanded headquarters and laboratories in the robust gene and cell therapy epicenter of Philadelphia’s University City and welcomes the appointments of Eric Pastor as Senior Vice President of Technology Development and Operations and Maria Limberis, PhD, as Vice President of Research

Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia

13 Oct , 2020 Press Releases

Spirovant Sciences CEO Joan Lau selected to receive the Ernst & Young LLP (EY US) Entrepreneur of The Year 2020 Award in Greater Philadelphia by an independent panel of judges.

Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal

7 Oct , 2020 Press Releases

Spirovant announces that CEO Joan Lau, PhD, has been named a 2020 Woman of Distinction by the Philadelphia Business Journal. The award will be presented in a virtual ceremony on November 12 at 11 am.

FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis

24 Sep , 2020 Press Releases

Spirovant announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis.

FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis

24 Sep , 2020 News

Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis.

Spirovant CEO Joan Lau Named Finalist for EY Entrepreneur of The Year® in Greater Philadelphia

3 Sep , 2020 Press Releases

Spirovant’s CEO, Joan Lau, PhD, has been named finalist for the Ernst & Young LLP (EY US) Entrepreneur of the Year 2020 Award in Greater Philadelphia, honoring entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world.

Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer

13 May , 2020 News

Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis (CF), today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery.

Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer

13 May , 2020 Press Releases

Spirovant Sciences today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery with 20+ years of research and executive leadership experience, most recently at MedImmune, AstraZeneca’s global biologics organization.

Philadelphia gene therapy company battling cystic fibrosis gets a new owner

7 Jan , 2020 News

Philadelphia gene therapy company Spirovant Sciences changed owners twice in 2019— including being acquired by Sumitomo Dainippon Pharma of Japan last week as part of a $3 billion deal — and its CEO couldn’t be happier.

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

30 Dec , 2019 News

Effective December 27, 2019, DSP has acquired from Roivant 100% of “Sumitovant Biopharma,” a newly formed company, and Roivant’s ownership interest in the five subsidiary companies, including Spirovant, that comprise Sumitovant.

1 2 Next »

Recent Posts

  • Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership
  • Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia
  • Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal
  • FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis
  • FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis
Spirovant Sciences, Inc.
3675 Market Street, Suite 200
Philadelphia, PA 19104
info@spirovant.com
(267) 244-8206


© Copyright 2021 | Terms of Use | Privacy Policy